ArticleInternational journal of clinical and experimental pathology2017
Expression of RSK4 in lung adenocarcinoma tissue and its clinicopathological value: a study based on RNA-seq data and immunohistochemistry.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Expression of RSK4 protein in non-small cell lung cancer tissues, adjacent tissues and its correlation with clinicopathological features.American journal of translational research · 2024Article
- Ribosomal S6 protein kinase 4 promotes resistance to EZH2 inhibitors in glioblastoma.Cancer gene therapy · 2023Article
- Ribosomal S6 kinase 4 (RSK4) tumor suppressor gene promoter methylation status in ovarian cancer.Molecular biology reports · 2023Article
- Differential Expression of RSK4 Transcript Isoforms in Cancer and Its Clinical Relevance.International journal of molecular sciences · 2022Article
- Raltitrexed regulates proliferation and apoptosis of HGC-27 cells by upregulating RSK4.BMC pharmacology & toxicology · 2022Article
- Establishment of a Prognostic Prediction and Drug Selection Model for Patients with Clear Cell Renal Cell Carcinoma by Multiomics Data Analysis.Oxidative medicine and cellular longevity · 2022Article
- MiR-548d-3p Promotes Gastric Cancer by Targeting RSK4.Cancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical significance of p90-kDa ribosomal S6 kinase (RSK) family members in lung adenocarcinoma (LUAD) is unknown. The aim of this study was to analyze genomic alterations in RSK family membersand investigate the expression and clinicopathological significance of RSK4 in LUAD tissues. Genomic calterations of RSK family, overall survival, andinteraction networks were analyzed in patients with LUAD (n=522), using data from The Cancer Genome Atlas (TCGA) database. The expression of RSK4 protein was investigated in an independent cohort of patients with LUAD (n=127) by immunohistochemistry, and relationships between RSK4 protein levels and clinicopathological parameters of LUAD were analyzed. Patients with LUAD with RSK genomic alterations had significantly better overall survival than patients without alterations (P=0.026).
Indexed as
Identifiers
31966496PMC6966026W3026933811What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.